Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Laboratorio de David Baker en la Universidad de Washington desarrolla enzimas con IA para fabricación sostenible de fármacos.

After AI antibodies and peptides, UW’s Baker Lab now tackles computer-generated enzymes

13 de febrero de 2025

El laboratorio de David Baker en la Universidad de Washington es pionero en el desarrollo de enzimas generadas mediante inteligencia artificial, que podrían revolucionar la farmacia al sintetizar de manera eficiente compuestos farmacéuticos sin necesidad de disolventes agresivos. Estas enzimas hechas a medida, diseñadas para catalizar diversas reacciones químicas, superan a los métodos tradicionales que modifican las proteínas existentes. De acuerdo con Baker y su equipo, al crear nuevas serina hidrolasas, el laboratorio pretende mejorar el desarrollo y la sostenibilidad de los fármacos, transformando potencialmente los procesos de fabricación farmacéutica y reduciendo el impacto ambiental.